Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.

Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.

2.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.

Ann Hematol. 2018 May 27. doi: 10.1007/s00277-018-3365-y. [Epub ahead of print]

PMID:
29804268
3.

Chronic myeloproliferative neoplasms in the elderly.

Maffioli M, Orlandi E, Passamonti F.

Eur J Intern Med. 2018 May 22. pii: S0953-6205(18)30182-1. doi: 10.1016/j.ejim.2018.05.005. [Epub ahead of print]

PMID:
29793825
4.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
5.

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Passamonti F, Mora B, Barraco D, Maffioli M.

Curr Hematol Malig Rep. 2018 Apr 30. doi: 10.1007/s11899-018-0453-y. [Epub ahead of print] Review.

PMID:
29713873
6.

The role of JAK2 inhibitors in MPNs 7 years after approval.

Passamonti F, Maffioli M.

Blood. 2018 May 31;131(22):2426-2435. doi: 10.1182/blood-2018-01-791491. Epub 2018 Apr 12. Review.

PMID:
29650801
7.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Apr 5. pii: haematol.2017.185751. doi: 10.3324/haematol.2017.185751. [Epub ahead of print] No abstract available.

8.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

PMID:
29515238
9.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

10.

Antimicrobial susceptibility survey on bacterial agents of canine and feline urinary tract infections: Weight of the empirical treatment.

Rampacci E, Bottinelli M, Stefanetti V, Hyatt DR, Sgariglia E, Coletti M, Passamonti F.

J Glob Antimicrob Resist. 2018 Jun;13:192-196. doi: 10.1016/j.jgar.2018.01.011. Epub 2018 Feb 3.

PMID:
29408407
11.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.

Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.

PMID:
29396713
12.

Investigation of the antibiotic resistance and biofilm formation of Staphylococcus pseudintermedius strains isolated from canine pyoderma.

Stefanetti V, Bietta A, Pascucci L, Marenzoni ML, Coletti M, Franciosini MP, Passamonti F, Casagrande Proietti P.

Vet Ital. 2017 Dec 29;53(4):289-296. doi: 10.12834/VetIt.465.2275.6.

13.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
14.

Therapy of polycythemia vera: is it time to change?

Passamonti F, Maffioli M, Mora B.

Oncotarget. 2017 Nov 3;8(61):102759-102760. doi: 10.18632/oncotarget.22282. eCollection 2017 Nov 28. No abstract available.

15.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
16.

Pathology in Practice.

Lepri E, Beccati F, Miglio A, Passamonti F, Veronesi F, Mandara MT.

J Am Vet Med Assoc. 2017 Nov 15;251(10):1153-1156. doi: 10.2460/javma.251.10.1153. No abstract available.

PMID:
29099246
17.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
18.

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.

Maffioli M, Mora B, Passamonti F.

Clin Adv Hematol Oncol. 2017 Sep;15(9):700-707. Review.

PMID:
28949941
19.

DNA microarray assay and real-time PCR as useful tools for studying the respiratory tract Mycoplasma populations in young dairy calves.

Bottinelli M, Passamonti F, Rampacci E, Stefanetti V, Pochiero L, Coletti M, Rueca F, Hyatt DR, Schnee C.

J Med Microbiol. 2017 Sep;66(9):1342-1349. doi: 10.1099/jmm.0.000571. Epub 2017 Sep 4.

PMID:
28868997
20.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. No abstract available.

21.

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.

Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R.

Leukemia. 2018 Feb;32(2):438-449. doi: 10.1038/leu.2017.220. Epub 2017 Jul 12.

22.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
23.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
24.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. No abstract available.

PMID:
28465517
25.

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.

Merli M, Frigeni M, Gotti M, Grossi P, Bruno R, Passamonti F, Arcaini L.

Hepatology. 2017 Oct;66(4):1341-1343. doi: 10.1002/hep.29198. Epub 2017 Aug 26. No abstract available.

PMID:
28378929
26.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group.

Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.

27.

Umbilical infections in foals: microbiological investigation and management.

Rampacci E, Passamonti F, Bottinelli M, Stefanetti V, Cercone M, Nannarone S, Gialletti R, Beccati F, Coletti M, Pepe M.

Vet Rec. 2017 Jun 3;180(22):543. doi: 10.1136/vr.103999. Epub 2017 Mar 17.

PMID:
28314783
28.

Deep sequencing and variant analysis of an Italian pathogenic field strain of equine infectious anaemia virus.

Cappelli K, Cook RF, Stefanetti V, Passamonti F, Autorino GL, Scicluna MT, Coletti M, Verini Supplizi A, Capomaccio S.

Transbound Emerg Dis. 2017 Dec;64(6):2104-2112. doi: 10.1111/tbed.12631. Epub 2017 Mar 15.

PMID:
28299895
29.

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F.

Expert Opin Investig Drugs. 2017 Mar;26(3):367-373. doi: 10.1080/13543784.2017.1288213. Epub 2017 Feb 9. Review.

PMID:
28140696
30.

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G.

Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.

PMID:
27916398
31.

Update from the latest WHO classification of MPNs: a user's manual.

Passamonti F, Maffioli M.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542. Review.

PMID:
27913526
32.

A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion.

Pessina C, Basilico C, Genoni A, Meroni E, Elli L, Granata P, Righi R, Pallotti F, Mora B, Ferrario A, Passamonti F, Casalone R.

Leuk Lymphoma. 2017 Aug;58(8):1977-1980. doi: 10.1080/10428194.2016.1262952. Epub 2016 Dec 2. No abstract available.

PMID:
27911132
33.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.

Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. No abstract available.

PMID:
27885272
34.

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).

Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B.

Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382. Epub 2016 Nov 8.

35.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Erratum in: Leukemia. 2017 May;31(5):1252.

36.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T.

Leukemia. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283. Epub 2016 Oct 14.

PMID:
27740634
37.

Stored Canine Whole Blood Units: What is the Real Risk of Bacterial Contamination?

Miglio A, Stefanetti V, Antognoni MT, Cappelli K, Capomaccio S, Coletti M, Passamonti F.

J Vet Intern Med. 2016 Nov;30(6):1830-1837. doi: 10.1111/jvim.14593. Epub 2016 Oct 13.

38.

Detection of bacterial contamination and DNA quantification in stored blood units in 2 veterinary hospital blood banks.

Stefanetti V, Miglio A, Cappelli K, Capomaccio S, Sgariglia E, Marenzoni ML, Antognoni MT, Coletti M, Mangili V, Passamonti F.

Vet Clin Pathol. 2016 Sep;45(3):406-10. doi: 10.1111/vcp.12372. Epub 2016 Jul 11.

PMID:
27642138
39.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

40.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.

Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F.

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14. Review.

PMID:
27416486
41.

Management of Candida guilliermondii joint infection in a dog.

Bufalari A, Maggio C, Moretti G, Crovace A, Stefanetti V, Straubinger RK, Passamonti F.

Acta Vet Scand. 2016 Jul 8;58(1):47. doi: 10.1186/s13028-016-0227-2.

42.

Detection and DNA quantification of Enterococcus casseliflavus in a foal with septic meningitis.

Stefanetti V, Beccati F, Passamonti F, Sgariglia E, Coletti M, Vuerich M, Marenzoni ML.

J Am Vet Med Assoc. 2016 Jul 1;249(1):96-100. doi: 10.2460/javma.249.1.96.

PMID:
27308888
43.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM.

Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4.

44.

Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.

Mesa RA, Passamonti F.

Am Soc Clin Oncol Educ Book. 2016;35:e324-35. doi: 10.14694/EDBK_159322. Review.

45.

High Expression of Endogenous Retroviral Envelope Gene in the Equine Fetal Part of the Placenta.

Stefanetti V, Marenzoni ML, Passamonti F, Cappelli K, Garcia-Etxebarria K, Coletti M, Capomaccio S.

PLoS One. 2016 May 13;11(5):e0155603. doi: 10.1371/journal.pone.0155603. eCollection 2016.

46.

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, Scalzulli PR, Rumi E, Dragani A, Martinelli V, Santoro C, Randi ML, Tagariello G, Candoni A, Cattaneo D, Ricco A, Palmieri R, Liberati MA, Langella M, Rago A, Bergamaschi M, Monari P, Miglio R, Santoro U, Cacciola R, Rupoli S, Mastrullo L, Musto P, Mazzucconi MG, Vignetti M, Cortelezzi A, Vianelli N, Martino B, De Stefano V, Passamonti F, Vannucchi AM; Registro Italiano Trombocitemie RIT.

Leuk Res. 2016 Jul;46:18-25. doi: 10.1016/j.leukres.2016.04.004. Epub 2016 Apr 7.

PMID:
27107744
47.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ.

Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.

48.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA.

Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

49.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11.

50.

New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.

Passamonti F, Mora B, Maffioli M.

Curr Opin Hematol. 2016 Mar;23(2):137-43. doi: 10.1097/MOH.0000000000000218. Review.

PMID:
26825696

Supplemental Content

Loading ...
Support Center